Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer's.

Drug Delivery
Natalia Lopez-BarbosaJuan C Cruz

Abstract

Therapeutic drugs for Alzheimer's disease have been extensively studied due to its recurrence and abundance among neurodegenerative diseases. It is thought that the accumulation of amyloid precursor protein (APP) products, a consequence of an up-regulation of the β-site APP-cleaving enzyme 1 (BACE1), is the main triggering mechanism during the early stages of the disease. This study aims to explore the ability of a multifunctional conjugate based on magnetite nanoparticles for the cellular delivery of siRNA against the expression of the BACE1 gene. We immobilized the siRNA strand on PEGylated magnetite nanoparticles and investigated the effects on biocompatibility and efficacy of the conjugation. Similarly, we co-immobilized the translocating protein OmpA on PEGylated nanoparticles to enhance cellular uptake and endosomal escape. BACE1 suppression was statistically significant in HFF-1 cells, without any presence of a cytotoxic effect. The delivery of the nanoconjugate was achieved through endocytosis pathways, where endosome formation was likely escaped due to the proton-sponge effect characteristic of PEGylated nanoparticles or mainly by direct translocation in the case of OmpA/PEGylated nanoparticles.

References

Nov 24, 2006·Proceedings of the National Academy of Sciences of the United States of America·Xiulian SunWeihong Song
Nov 19, 2008·Pharmaceutical Research·Won Jong Kim, Sung Wan Kim
Dec 17, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stephanie DavidCatherine Passirani
Feb 18, 2010·Chemical Communications : Chem Comm·Maisie J JoralemonTodd Emrick
Jan 29, 2011·Angewandte Chemie·Ajay S KarakotiSudipta Seal
Mar 23, 2011·Nature Biotechnology·Lydia Alvarez-ErvitiMatthew J A Wood
Apr 12, 2011·Nature Biotechnology·Jasper G van den BoornGunther Hartmann
Mar 6, 2012·Materials Today·Zachary R StephenMiqin Zhang
Mar 22, 2014·Journal of Neurochemistry·Robert VassarStefan F Lichtenthaler
Oct 17, 2014·The Journal of Physical Chemistry. B·Dong YangJianhua Hu
May 20, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer’s Association
May 27, 2015·Nature Neuroscience·Karl Herrup
Jun 17, 2015·Proceedings of the National Academy of Sciences of the United States of America·Grant T CorbettKalipada Pahan
Aug 19, 2015·Nature Reviews. Genetics·Anders Wittrup, Judy Lieberman
Nov 1, 2016·Journal of Neurochemistry·Eric Karran, Bart De Strooper
Feb 6, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Laura I SelbyAngus P R Johnston
Feb 27, 2017·Nanoscale Research Letters·Tetiana TatarchukMichał Pacia
Feb 28, 2017·Scientific Reports·Tatiana P VelloCarlos C B Bufon
May 5, 2017·Frontiers in Molecular Neuroscience·Riqiang Yan
Jan 20, 2021·ACS Biomaterials Science & Engineering·Natalia Lopez-BarbosaJuan C Cruz

❮ Previous
Next ❯

Citations

Mar 9, 2021·Neurochemistry International·Mukta AgrawalAmit Alexander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Endosomes

Dysfunctional endosomal trafficking may be associated with Alzheimer’s disease (AD) pathology. Targeting the endosome may advance treatment options for AD. Here is the latest research on endosomes and AD.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.